Efficacy and toxicity of mammalian target rapamycin inhibitors in patients with metastatic renal cell carcinoma with renal insufficiency

The Korean Cancer Study Group GU 14-08

Ki Hyang Kim, Joo Hoon Kim, Ji Young Lee, Hyo Song Kim, Su Jin Heo, Ji Hyung Kim, Ho Young Kim, SunYoung Rha

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Purpose We evaluated the efficacy and toxicity of mammalian target rapamycin inhibitors in Korean patients with metastatic renal cell carcinoma (mRCC) with chronic renal insufficiency not requiring dialysis. Materials and Methods Korean patients with mRCC and chronic renal insufficiency not requiring dialysis treated with everolimus or temsirolimus between January 2008 and December 2014 were included. Patient characteristics, clinical outcomes, and toxicities were evaluated. Overall survival (OS) and progression-free survival (PFS) durations were evaluated according to the degree of renal impairment. Results Eighteen patients were considered eligible for the study (median age, 59 years). The median glomerular filtration rate was 51.5 mL/min/1.73 m 2 . The best response was partial response in six patients and stable disease in 11 patients. The median PFS and OS durations were 8 months (95% confidence interval [CI], 0 to 20.4) and 32 months (95% CI, 27.5 to 36.5), respectively. The most common non-hematologic and grade 3/4 adverse events included stomatitis, fatigue, flu-like symptoms, and anorexia as well as elevated creatinine level. Conclusion Mammalian target rapamycin inhibitors were efficacious and did not increase toxicity in Korean patients with mRCC and chronic renal insufficiency not requiring dialysis.

Original languageEnglish
Pages (from-to)1286-1292
Number of pages7
JournalCancer Research and Treatment
Volume48
Issue number4
DOIs
Publication statusPublished - 2016 Jan 1

Fingerprint

Sirolimus
Renal Cell Carcinoma
Renal Insufficiency
Chronic Renal Insufficiency
Neoplasms
Dialysis
Disease-Free Survival
Confidence Intervals
Stomatitis
Survival
Anorexia
Glomerular Filtration Rate
Fatigue
Creatinine
Kidney

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Kim, Ki Hyang ; Kim, Joo Hoon ; Lee, Ji Young ; Kim, Hyo Song ; Heo, Su Jin ; Kim, Ji Hyung ; Kim, Ho Young ; Rha, SunYoung. / Efficacy and toxicity of mammalian target rapamycin inhibitors in patients with metastatic renal cell carcinoma with renal insufficiency : The Korean Cancer Study Group GU 14-08. In: Cancer Research and Treatment. 2016 ; Vol. 48, No. 4. pp. 1286-1292.
@article{16e377d4a8d74605a9f63a5db2b21c39,
title = "Efficacy and toxicity of mammalian target rapamycin inhibitors in patients with metastatic renal cell carcinoma with renal insufficiency: The Korean Cancer Study Group GU 14-08",
abstract = "Purpose We evaluated the efficacy and toxicity of mammalian target rapamycin inhibitors in Korean patients with metastatic renal cell carcinoma (mRCC) with chronic renal insufficiency not requiring dialysis. Materials and Methods Korean patients with mRCC and chronic renal insufficiency not requiring dialysis treated with everolimus or temsirolimus between January 2008 and December 2014 were included. Patient characteristics, clinical outcomes, and toxicities were evaluated. Overall survival (OS) and progression-free survival (PFS) durations were evaluated according to the degree of renal impairment. Results Eighteen patients were considered eligible for the study (median age, 59 years). The median glomerular filtration rate was 51.5 mL/min/1.73 m 2 . The best response was partial response in six patients and stable disease in 11 patients. The median PFS and OS durations were 8 months (95{\%} confidence interval [CI], 0 to 20.4) and 32 months (95{\%} CI, 27.5 to 36.5), respectively. The most common non-hematologic and grade 3/4 adverse events included stomatitis, fatigue, flu-like symptoms, and anorexia as well as elevated creatinine level. Conclusion Mammalian target rapamycin inhibitors were efficacious and did not increase toxicity in Korean patients with mRCC and chronic renal insufficiency not requiring dialysis.",
author = "Kim, {Ki Hyang} and Kim, {Joo Hoon} and Lee, {Ji Young} and Kim, {Hyo Song} and Heo, {Su Jin} and Kim, {Ji Hyung} and Kim, {Ho Young} and SunYoung Rha",
year = "2016",
month = "1",
day = "1",
doi = "10.4143/crt.2016.018",
language = "English",
volume = "48",
pages = "1286--1292",
journal = "Cancer Research and Treatment",
issn = "1598-2998",
publisher = "Korean Cancer Association",
number = "4",

}

Efficacy and toxicity of mammalian target rapamycin inhibitors in patients with metastatic renal cell carcinoma with renal insufficiency : The Korean Cancer Study Group GU 14-08. / Kim, Ki Hyang; Kim, Joo Hoon; Lee, Ji Young; Kim, Hyo Song; Heo, Su Jin; Kim, Ji Hyung; Kim, Ho Young; Rha, SunYoung.

In: Cancer Research and Treatment, Vol. 48, No. 4, 01.01.2016, p. 1286-1292.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Efficacy and toxicity of mammalian target rapamycin inhibitors in patients with metastatic renal cell carcinoma with renal insufficiency

T2 - The Korean Cancer Study Group GU 14-08

AU - Kim, Ki Hyang

AU - Kim, Joo Hoon

AU - Lee, Ji Young

AU - Kim, Hyo Song

AU - Heo, Su Jin

AU - Kim, Ji Hyung

AU - Kim, Ho Young

AU - Rha, SunYoung

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Purpose We evaluated the efficacy and toxicity of mammalian target rapamycin inhibitors in Korean patients with metastatic renal cell carcinoma (mRCC) with chronic renal insufficiency not requiring dialysis. Materials and Methods Korean patients with mRCC and chronic renal insufficiency not requiring dialysis treated with everolimus or temsirolimus between January 2008 and December 2014 were included. Patient characteristics, clinical outcomes, and toxicities were evaluated. Overall survival (OS) and progression-free survival (PFS) durations were evaluated according to the degree of renal impairment. Results Eighteen patients were considered eligible for the study (median age, 59 years). The median glomerular filtration rate was 51.5 mL/min/1.73 m 2 . The best response was partial response in six patients and stable disease in 11 patients. The median PFS and OS durations were 8 months (95% confidence interval [CI], 0 to 20.4) and 32 months (95% CI, 27.5 to 36.5), respectively. The most common non-hematologic and grade 3/4 adverse events included stomatitis, fatigue, flu-like symptoms, and anorexia as well as elevated creatinine level. Conclusion Mammalian target rapamycin inhibitors were efficacious and did not increase toxicity in Korean patients with mRCC and chronic renal insufficiency not requiring dialysis.

AB - Purpose We evaluated the efficacy and toxicity of mammalian target rapamycin inhibitors in Korean patients with metastatic renal cell carcinoma (mRCC) with chronic renal insufficiency not requiring dialysis. Materials and Methods Korean patients with mRCC and chronic renal insufficiency not requiring dialysis treated with everolimus or temsirolimus between January 2008 and December 2014 were included. Patient characteristics, clinical outcomes, and toxicities were evaluated. Overall survival (OS) and progression-free survival (PFS) durations were evaluated according to the degree of renal impairment. Results Eighteen patients were considered eligible for the study (median age, 59 years). The median glomerular filtration rate was 51.5 mL/min/1.73 m 2 . The best response was partial response in six patients and stable disease in 11 patients. The median PFS and OS durations were 8 months (95% confidence interval [CI], 0 to 20.4) and 32 months (95% CI, 27.5 to 36.5), respectively. The most common non-hematologic and grade 3/4 adverse events included stomatitis, fatigue, flu-like symptoms, and anorexia as well as elevated creatinine level. Conclusion Mammalian target rapamycin inhibitors were efficacious and did not increase toxicity in Korean patients with mRCC and chronic renal insufficiency not requiring dialysis.

UR - http://www.scopus.com/inward/record.url?scp=84996957282&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84996957282&partnerID=8YFLogxK

U2 - 10.4143/crt.2016.018

DO - 10.4143/crt.2016.018

M3 - Article

VL - 48

SP - 1286

EP - 1292

JO - Cancer Research and Treatment

JF - Cancer Research and Treatment

SN - 1598-2998

IS - 4

ER -